Pulmonary hypertension complicating congenital heart disease

Current Cardiology Reports

Volumn 11, Issue 4, 2009, Pages 314-320

  Rame, J Eduardo ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERAPROST; BONE MORPHOGENETIC PROTEIN 2; BOSENTAN; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; FIBROBLAST GROWTH FACTOR; ILOPROST; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTANOID; SILDENAFIL; THROMBOXANE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNIPROST;

CLINICAL TRIAL; COMORBIDITY; CONGENITAL HEART DISEASE; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EISENMENGER COMPLEX; ENDOTHELIAL DYSFUNCTION; EXERCISE; FUNCTIONAL STATUS; GENE MUTATION; HEART HEMODYNAMICS; HEART TRANSPLANTATION; HUMAN; LIFE EXPECTANCY; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG HEMODYNAMICS; LUNG TRANSPLANTATION; MATHEMATICAL ANALYSIS; OXIDATIVE STRESS; PRESSURE GRADIENT; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIHYPERTENSIVE AGENTS; ENDOTHELIN-1; HEART DEFECTS, CONGENITAL; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 67650257478     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-009-0045-5     Document Type: Review

References (51)

1. Hickam JB, Cargill WH: Effect of exercise on cardiac output and pulmonary arterial pressure in normal persons and in patients with cardiovascular disease and pulmonary emphysema. J Clin Invest 1948, 27:10-23.
2. Riley RL, Himmelstein A, et al.: Studies of the pulmonary circulation at rest and during exercise in normal individuals and in patients with chronic pulmonary disease. Am J Physiol 1948, 152:372-382.
3. Black SM, Bekker JM, McMullan DM, et al.: Alterations in nitric oxide production in 8-week-old lambs with increased pulmonary blood flow. Pediatr Res 2002, 52:233-244.
4. Black SM, Sanchez LS, Mata-Greenwood E, et al.: SGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001, 281:L1051-L1057.
5. Black SM, Kumar S, Wiseman D, et al.: Pediatric pulmonary hypertension: roles of endothelin-1 and nitric oxide. Clin Hemorheol Microcirc 2007, 37:111-120.
6. Black SM, Mata-Greenwood E, Dettman RW, et al.: Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow. Circulation 2003, 108:1646-1654.
7. Campbell M: Natural history of ventricular septal defect. Br Heart J 1971, 33:246-257.
8. Cherian G, Uthaman CB, Durairaj M, et al.: Pulmonary hypertension in isolated secundum atrial septal defect: High frequency in young patients. Am Heart J 1983, 105:952-957.
9. Keith JD, Rose V, Collins G, Kidd BS: Ventricular septal defect. Incidence, morbidity, and mortality in various age groups. Br Heart J 1971, 33(Suppl):81-87.
10. Steele PM, Fuster V, Cohen M, et al.: Isolated atrial septal defect with pulmonary vascular obstructive disease - long-term follow-up and prediction of outcome after surgical correction. Circulation 1987, 76:1037-1042.
11. Heath D, Edwards JE: The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958, 18:533-547.
12. Meyrick B, Reid L: Ultrastructural findings in lung biopsy material from children with congenital heart defects. Am J Pathol 1980, 101:527-542.
13. Rabinovitch M, Bothwell T, Hayakawa BN, et al.: Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. A correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest 1986, 55:632-653.
14. Rabinovitch M, Haworth SG, Castaneda AR, et al.: Lung biopsy in congenital heart disease: A morphometric approach to pulmonary vascular disease. Circulation 1978, 58:1107-1122.
15. Rabinovitch M, Keane JF, Norwood WI, et al.: Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects. Circulation 1984, 69:655-667.
16. Brennan LA, Steinhorn RH, Wedgwood S, et al.: Increased superoxide generation is associated with pulmonary hypertension in fetal lambs: A role for NADPH oxidase. Circ Res 2003, 92:683-691.
17. Brennan LA, Wedgwood S, Bekker JM, Black SM: Nitric oxide activates p21ras and leads to the inhibition of endothelial NO synthase by protein nitration. DNA Cell Biol 2003, 22:317-328.
18. Wedgwood S, Black SM: Role of reactive oxygen species in vascular remodeling associated with pulmonary hypertension. Antioxid Redox Signal 2003, 5:759-769.
19. Wedgwood S, Black SM: Endothelin-1 decreases endothelial NOS expression and activity through ETA receptor-mediated generation of hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol 2005, 288:L480-L487.
20. Wedgwood S, Dettman RW, Black SM: ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am J Physiol Lung Cell Mol Physiol 2001, 281:L1058-L1067.
21. Wedgwood S, McMullan DM, Bekker JM, et al.: Role for endothelin-1-induced superoxide and peroxynitrite production in rebound pulmonary hypertension associated with inhaled nitric oxide therapy. Circ Res 2001, 89:357-364.
22. Wedgwood S, Steinhorn RH, Bunderson M, et al.: Increased hydrogen peroxide downregulates soluble guanylate cyclase in the lungs of lambs with persistent pulmonary hypertension of the newborn. Am J Physiol Lung Cell Mol Physiol 2005, 289:L660-L666.
23. Cornfield DN, Resnik ER, Herron JM, et al.: Pulmonary vascular K+ channel expression and vasoreactivity in a model of congenital heart disease. Am J Physiol Lung Cell Mol Physiol 2002, 283:L1210-L1219.
24. Black SM, DeVol JM, Wedgwood S: Regulation of fibroblast growth factor-2 expression in pulmonary arterial smooth muscle cells involves increased reactive oxygen species generation. Am J Physiol Cell Physiol 2008, 294:C345-C354.
25. Black SM, Grobe A, Mata-Greenwood E, Noskina Y: Cyclic stretch increases VEGF expression in pulmonary arterial smooth muscle cells via TGF-1 and reactive oxygen species: A requirement for NAD(P)H oxidase. Conf Proc IEEE Eng Med Biol Soc 2004, 7:5053-5056.
26. Mata-Greenwood E, Grobe A, Kumar S, et al.: Cyclic stretch increases VEGF expression in pulmonary arterial smooth muscle cells via TGF-beta1 and reactive oxygen species: A requirement for NAD(P)H oxidase. Am J Physiol Lung Cell Mol Physiol 2005, 289:L288-L289.
27. Mata-Greenwood E, Meyrick B, Steinhorn RH, et al.: Alterations in TGF-beta1 expression in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2003, 285:L209-L221.
28. Wedgwood S, Devol JM, Grobe A, et al.: Fibroblast growth factor-2 expression is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Pediatr Res 2007, 61:32-36.
29. Roberts KE, McElroy JJ, Wong WP, et al.: BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 2004, 24:371-374.
30. Cantor WJ, Harrison DA, Moussadji JS, et al.: Determinants of survival and length of survival in adults with Eisenmenger syndrome. Am J Cardiol 1999, 84:677-681.
31. D'Alonzo GE, Barst RJ, Ayres SM, et al.: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
32. Galie N, Beghetti M, Gatzoulis MA, et al.: Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006, 114:48-54.
33. Gatzoulis MA, Beghetti M, Galie N, et al.: Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension study. Int J Cardiol 2008, 127:27-32.
34. Diller GP, Dimopoulos K, Kaya MG, et al.: Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart 2007, 93:974-976.
35. Rosenzweig EB, Barker L, Barst RJ: Sitaxsentan treatment in patients with Eisenmenger syndrome [abstract]. Circulation 2007, 116(Suppl II):457.
36. Chau EM, Fan KY, Chow WH: Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007, 120:301-305.
37. Humpl T, Reyes JT, Holtby H, et al.: Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005, 111:3274-3280.
38. Lim ZS, Salmon AP, Vettukattil JJ, Veldtman GR: Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects. Int J Cardiol 2007, 118:178-182.
39. Mukhopadhyay S, Sharma M, Ramakrishnan S, et al.: Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: A preliminary observational study. Circulation 2006, 114:1807-1810.
40. Beghetti M, GaliA N: Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 2009, 53:733-740.
41. Fernandes SM, Newburger JW, Lang P, et al.: Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol 2003, 91:632-635.
42. Hallioglu O, Dilber E, Celiker A: Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am J Cardiol 2003, 92:1007-1009.
43. Limsuwan A, Khosithseth A, Wanichkul S, Khowsathit P: Aerosolized iloprost for pulmonary vasoreactivity testing in children with long-standing pulmonary hypertension related to congenital heart disease. Catheter Cardiovasc Interv 2009, 73:98-104.
44. Limsuwan A, Pienvichit P, Khowsathit P: Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease. Pediatr Cardiol 2005, 26:787-791.
45. Limsuwan A, Wanitkul S, Khosithset A, et al.: Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. Int J Cardiol 2007 Dec 18 (Epub ahead of print).
46. Okyay K, Cemri M, Boyac B, et al.: Use of long-term combined therapy with inhaled iloprost and oral sildenafil in an adult patient with Eisenmenger syndrome. Cardiol Rev 2005, 13:312-314.
47. Rosenzweig EB, Kerstein D, Barst RJ: Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999, 99:1858-1865.
48. Frost AE, Quinones MA, Zoghbi WA, Noon GP: Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant 2005, 24:501-503.
49. Hirabayashi A, Miyaji K, Akagi T: Continuous epoprostenol therapy and septal defect closure in a patient with severe pulmonary hypertension. Catheter Cardiovasc Interv 2009, 73:688-691.
50. Schwerzmann M, Zafar M, McLaughlin PR, et al.: Atrial septal defect closure in a patient with "irreversible" pulmonary hypertensive arteriopathy. Int J Cardiol 2006, 110:104-107.
51. Yamauchi H, Yamaki S, Fujii M, et al.: Atrial septal defect with borderline pulmonary vascular disease: Surgery and long-term oral prostacyclin therapy for recalcitrant pulmonary hypertension. Jpn J Thorac Cardiovasc Surg 2004, 52:213-216.